ERAS
Price
$1.52
Change
+$0.02 (+1.33%)
Updated
Jul 21, 04:00 PM (EDT)
Capitalization
424.93M
17 days until earnings call
LRMR
Price
$3.29
Change
+$0.08 (+2.49%)
Updated
Jul 21, 04:22 PM (EDT)
Capitalization
205.53M
17 days until earnings call
Interact to see
Advertisement

ERAS vs LRMR

Header iconERAS vs LRMR Comparison
Open Charts ERAS vs LRMRBanner chart's image
Erasca
Price$1.52
Change+$0.02 (+1.33%)
Volume$469
Capitalization424.93M
Larimar Therapeutics
Price$3.29
Change+$0.08 (+2.49%)
Volume$100
Capitalization205.53M
ERAS vs LRMR Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. LRMR commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and LRMR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (ERAS: $1.50 vs. LRMR: $3.21)
Brand notoriety: ERAS and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 55% vs. LRMR: 44%
Market capitalization -- ERAS: $424.93M vs. LRMR: $205.53M
ERAS [@Biotechnology] is valued at $424.93M. LRMR’s [@Biotechnology] market capitalization is $205.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while LRMR’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 2 bearish.
  • LRMR’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than LRMR.

Price Growth

ERAS (@Biotechnology) experienced а +3.45% price change this week, while LRMR (@Biotechnology) price change was -5.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.54%. For the same industry, the average monthly price growth was +15.97%, and the average quarterly price growth was +34.82%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

LRMR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+2.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($425M) has a higher market cap than LRMR($206M). LRMR YTD gains are higher at: -17.054 vs. ERAS (-40.239). LRMR has higher annual earnings (EBITDA): -105.02M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. LRMR (158M). LRMR has less debt than ERAS: LRMR (4.87M) vs ERAS (50.8M). ERAS (0) and LRMR (0) have equivalent revenues.
ERASLRMRERAS / LRMR
Capitalization425M206M206%
EBITDA-150.24M-105.02M143%
Gain YTD-40.239-17.054236%
P/E RatioN/AN/A-
Revenue00-
Total Cash305M158M193%
Total Debt50.8M4.87M1,044%
FUNDAMENTALS RATINGS
LRMR: Fundamental Ratings
LRMR
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASLRMR
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
86%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 5 days ago
86%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 25 days ago
89%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NRBT0.03N/A
+9.88%
Novus Robotics, Inc.
NUVSF10.220.15
+1.49%
NuVista Energy Ltd.
EVSYX26.100.04
+0.15%
Allspring Disciplined US Core Admin
AZNCX9.730.01
+0.10%
Virtus Income & Growth C
GMGMF0.57-0.02
-2.87%
Graphene Manufacturing Group Ltd.

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+0.67%
RVMD - ERAS
54%
Loosely correlated
-1.92%
XNCR - ERAS
54%
Loosely correlated
-1.10%
OCUL - ERAS
53%
Loosely correlated
-0.44%
BEAM - ERAS
53%
Loosely correlated
+1.47%
ACLX - ERAS
52%
Loosely correlated
-4.74%
More

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-3.31%
ERAS - LRMR
51%
Loosely correlated
+0.67%
ACLX - LRMR
50%
Loosely correlated
-4.74%
OCUL - LRMR
49%
Loosely correlated
-0.44%
SYRE - LRMR
49%
Loosely correlated
-3.55%
ALEC - LRMR
49%
Loosely correlated
-4.79%
More